Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.

Autor: Murphy RJ; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. Electronic address: rmur077@aucklanduni.ac.nz., Sumner R; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Evans W; Mana Health, Auckland, New Zealand., Ponton R; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Ram S; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Godfrey K; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand; Centre for Psychedelic Research, Department of Psychiatry, Imperial College London, London, England, UK., Forsyth A; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Cavadino A; Epidemiology and Biostatistics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Krishnamurthy Naga V; Department of Psychological Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Smith T; Te Whatu Ora, Auckland, New Zealand., Hoeh NR; Department of Psychological Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Menkes DB; Department of Psychological Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Muthukumaraswamy S; School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. Electronic address: sd.muthu@auckland.ac.nz.
Jazyk: angličtina
Zdroj: Biological psychiatry [Biol Psychiatry] 2023 Sep 15; Vol. 94 (6), pp. 511-521. Date of Electronic Publication: 2023 Mar 28.
DOI: 10.1016/j.biopsych.2023.03.013
Abstrakt: Background: Microdosing psychedelic drugs is a widespread social phenomenon with diverse benefits claimed for mood and cognition. Randomized controlled trials have failed to support these claims, but the laboratory-based dosing in trials conducted to date may have limited ecological validity.
Methods: Healthy male volunteers were randomized into lysergic acid diethylamide (LSD) (n = 40) and placebo (n = 40) groups and received 14 doses of either 10 μg LSD or an inactive placebo every 3 days for 6 weeks. First doses were given in a supervised laboratory setting, with other doses self-administered in a naturalistic setting. Results of safety data, blinding, daily questionnaires, expectancy, and pre-/postintervention psychometrics and cognitive tasks are presented here.
Results: The most notable reported adverse event was treatment-related anxiety, which prompted the withdrawal of 4 participants from the LSD group. Daily questionnaires showed credible evidence (>99% posterior probability) of improved ratings of creativity, connectedness, energy, happiness, irritability, and wellness on dose days compared with nondose days, and these effects remained when controlling for preintervention expectancy. No questionnaire or cognitive task showed a credible change between baseline and 6-week assessment time points.
Conclusions: Microdosing LSD appears to be relatively safe in healthy adult men, notwithstanding a risk of anxiety. While microdosing elicited transient increases in scales associated with mood-elevating effects, it was not sufficient to promote enduring changes to overall mood or cognition in healthy adults. Future microdosing trials in clinical populations will require the use of active placebos to control for placebo effects and dose titration to adjust for interindividual variability in drug response.
(Copyright © 2023 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: